29Jul
National Retailer Pulls CBD Products From Shelves in Response to FDA Warning to Product Manufacturer
On Monday, July 22, the U.S. Food and Drug Administration (FDA) took a rare and significant step in issuing a warning letter to Curaleaf Holdings, Inc. (Curaleaf), one of the country’s larger producers of CBD-based products, regarding Curaleaf’s...
By:
Manatt, Phelps & Phillips, LLP
Related
Ever wonder what the Occupational Safety and Health Administration (OSHA) would do if an employer re...
Read More >
On August 9, 2019, the Department of Labor (“DOL”) issued USERRA Fact Sheet 1, providing guidance ...
Read More >
Antitrust enforcers in the United States and European Union (EU) remained active in 2019, and recent...
Read More >
Many governmental 457(b) deferred compensation and 401(a) defined contribution plan sponsors do not ...
Read More >
Earlier this month, New York State passed a new law prohibiting discrimination against employees bas...
Read More >
Our monthly edition of the “Government Contracts Regulatory and Legislative Update” offers a summa...
Read More >